Vi bøger
Levering: 1 - 2 hverdage

Bøger i Progress in Drug Research serien

Filter
Filter
Sorter efterSorter Serie rækkefølge
  • - Advances and Problems
     
    1.116,95 kr.

    The main emphasis of the book lies in antifungal therapy: the most relevant information on the present state of the art of antifungal chemotherapy for dermatomycoses, subcutaneous and invasive mycoses is summarized, and open questions and unsolved problems are presented.

  •  
    1.843,95 kr.

    In a real tour de force of pharmacological literature, this edited volume's chapters highlight the biodiversity-driven approaches which are now of eminent importance in natural products research.

  •  
    736,95 kr.

    Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide.

  • - Pharmaceutical Opportunities
     
    2.048,95 kr.

    Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

  •  
    1.487,95 kr.

    This volume provides an up-to-date account of the achievements pertaining to the application of capsaicin and capsaicin-like molecules in the therapy of various human ailments such as pain, non-allergic rhinitis, obesity, tumors and gastrointestinal, dermatologic and urologic disorders.

  •  
    736,95 kr.

    Hypertension is one of the cardiovascular diseases which is most common throughout the world. Such hypertension is termed as essential hypertension. In a few cases (5- 15%), the hypertension is secondary to definable causes, such as renal artery stenosis, a pheochromocytoma, or an endocrine disorder.

  •  
    1.692,95 kr.

    Volume 63 of "Progress in Drug Research" is devoted to recent developments in targeted cancer therapy. Significant advances in the fields of molecular and tumor biology over the past decade have led to this exciting new era in c- cer therapeutics with an intensive effort in rationally-designed cancer the- peutic strategies directed against selective molecular targets. These selective approaches may ultimately lead to tailoring treatments to individual patients where molecular biomarkers of sensitivity to therapy are identified, prod- ing better tolerated therapies with less side effects than past experiences with cytotoxic cancer chemotherapy, and reducing cancer to a controlled, chronic state. This volume contains eleven chapters, including updated reviews on a range of targets, such as tumor angiogenesis, apoptosis/cell survival pa- ways, and various inhibitors of cyclin-dependent kinases, cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and histone deacetylases (HDAC). Additional topics, including target validation, polypharmacology and potential synergy of involving multiple targets, antisense approaches, animal models for preclinical development of targeted agents, and obstacles, including development of resistance are also presented. In addition, the p- ticular challenges involved in translating preclinical data to clinical appli- tion are discussed. It gives me great pleasure to present this new volume. I would like to express my gratitude to the chapter authors, to Birkhauser Verlag and, in particular, to Dr. Beatrice Menz and Ms. Gabriele Poppen for their assistance in compiling and editing this volume. April 2005 Richard M. Schultz vii Progress in Drug Research, Vol. 63 (R. M. Schultz, Ed.

  • af Norman K. Hollenberg, Steven W. Graves, Robert B. McCall, mfl.
    562,95 kr.

  • af Vijendra K. Singh, Margaret E. Gnegy, S. P. Gupta, mfl.
    1.113,95 kr.

    Volume 45 of "Progress in Drug Research" contains eight reviews and the various indexes which facilitate its use and establish the connection with the previous volumes.

  •  
    2.188,95 kr.

    Founded in 1959, this series encompasses all fields concerned with the development of new therapeutic drugs and the elucidation of their mechanisms of action, reflecting the increasingly complex nature of modern drug research.

  • - Pharmaceutical Opportunities
     
    2.061,95 kr.

    Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

  •  
    1.190,95 kr.

    This monograph examines the contribution of imaging modalities to the stages of drug discovery and development, from early target validation to their use in clinical development programs.

  • af Richard M. Schultz, Hao Wu, Eric J. Lien, mfl.
    2.221,95 kr.

    Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research.

  •  
    1.708,95 kr.

    The use of substances derived from plants, fungi, bacteria and marine organisms has a long tradition in medicine. It addresses the question why natural products display such a complex chemical information, what makes them often unique and what their characteristics are.

  • - Advances and Problems
     
    863,95 kr.

    The unfortunate appearance of AIDS, the manifold problems with herpesviruses and other viruses attacking humans have led to an enormous dynamism of worldwide research and to an immense increase in the corresponding literature. This title provides reviews on the development of antiviral agents in some important and widespread viral diseases.

  •  
    2.207,95 kr.

    This series provides extensive reviews on a wide spectrum of topical areas in pharmaceutical and pharmacological research. It encompasses all fields concerned with the development of new therapeutic drugs and the elucidation of their mechanisms of action.

Gør som tusindvis af andre bogelskere

Tilmeld dig nyhedsbrevet og få gode tilbud og inspiration til din næste læsning.